Shortly after my husband Nick and I moved our family from Australia to Denver in 2011, two pieces of news changed our lives in a matter of 2 months: we learned we had a third child on the way, and Nick was diagnosed with Stage 4 Melanoma.
Nick is determined to beat this so our children -- Locky (7), Hayley (5), and Evan (1) -- can grow up with Dad beside them. Nick takes on each new battle with melanoma with audacity -- determined to win and constantly assuring others that he will jump the next hurdle. And he always does.
Most of all, Nick shows incredible dedication to our kids every single day. A few weeks ago, he even slipped home from the hospital to make sure he got to watch the big game at home with Locky before surgery, and he doesn't miss a chance to take Hayley bike-riding or to teach little Evan a new word.
But we've hit a critical time in Nick's battle against cancer. While Stage 4 melanoma has long been considered incurable, a new anti-PD-1 ("PD-1") wonderdrug is showing remarkable results for patients like Nick. But the drug, which is being developed by BristolMyers Squibb and Merck, is still undergoing clinical trials and may not be available to the public for 12 to 18 months. My husband doesn’t have that long to wait.
I can't imagine life without Nick. I can't imagine telling Locky he has to watch the big game alone, telling Hayley that Daddy can't take her bike-riding anymore, or knowing that my youngest son won't even remember his dad. I can't live with that possibility and I won't. I will never stop fighting to save my husband.
Merck and Bristol-Myers Squibb have the power to grant Nick single patient access to PD-1 right away under compassionate use laws. We’ve been told that this is our last hope for saving my husband’s life.
I believe Nick can jump this last hurdle if Merck and Bristol-Myers Squibb give him that chance.
Please Australia, join Locky, Hayley, Evan, and me in asking Merck and Bristol-Myers Squibb to provide PD-1 to Nick, so he can win against melanoma.
Visit http://www.savelockysdad.com/ for more information about our story.